Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Pfizer Holds Career Planning Course for Female MRs
October 29, 2007
-
ARCHIVE Development of More Switch OTC Drugs Essential
October 29, 2007
-
ARCHIVE AstraZeneca Works to Create Easier-to-Work Environment for Female MRs
October 29, 2007
-
ARCHIVE Paltac to Stimulate OTC Drug Market by Merging with Kobashou
October 29, 2007
-
ARCHIVE MR Education Center Considers Radical Reform of MR Education System
October 29, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 29, 2007
-
ARCHIVE SEMINAR/Generics to Obtain 1/3 of Market for Antibacterials in 2016: Datamonitor
October 29, 2007
-
ARCHIVE Korosho to Increase Multinational Joint Trial Participation Rate under 5-Year Plan
October 29, 2007
-
ARCHIVE Consumption of EPO Decreased in 40% of Patients
October 29, 2007
-
ARCHIVE OHARA Pharm. Strengthens Product, Information Supply Systems
October 29, 2007
-
ARCHIVE Merck Ties UP with ImClone, BMS for Erbitux in Japan
October 29, 2007
-
ARCHIVE JGPMA Announces Goals to Promote Use of Generics
October 29, 2007
-
ARCHIVE Shionogi's Doripenem Debuts in US Market
October 29, 2007
-
ARCHIVE SURVEY/Analysis of Medical Bills Show Increases in Use of Generics: Korosho
October 29, 2007
-
ARCHIVE Infection-related Test Market for 2006 Reaches ¥82.5 Bil.: Fuji Keizai
October 29, 2007
-
ARCHIVE Action Program Issued by Korosho to Promote Use of Generics
October 29, 2007
-
ARCHIVE Kirin Pharma to Merge with Kyowa Hakko
October 29, 2007
-
ARCHIVE Korosho Presents List of Issues to Promote Use of Generics to Chuikyo
October 29, 2007
-
ARCHIVE More M&As Expected in Japanese Pharma Industry: Mr Eiki
October 29, 2007
-
ARCHIVE REGULATORY NEW IN BRIEF
October 22, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…